Nu-Med optimistic about nitric oxide prospects after patent ruling

Charlotte Edwards 16 August 2018 (Last Updated August 16th, 2018 16:13)

Nu-Med Plus, the medical nitric oxide delivery developer, is anticipating a favourable market environment for its products after recent patent rulings.

Nu-Med optimistic about nitric oxide prospects after patent ruling
As a medically essential gas, nitric oxide is always in demand. Credit: Andrew Smith.

Nu-Med Plus, the medical nitric oxide delivery developer, is anticipating a favourable market environment for its products after recent patent rulings.

Earlier this year, a Federal Circuit Court ruling invalidated the majority of a patent for a dominant nitric oxide producer which means more than one company will now be allowed to sell nitric oxide gas for medical use. More gas supply companies are therefore expected to enter and expand the medical nitric oxide market.

Now the monopoly of the market has been broken, Nu-Med Plus expects that market expansion will result in a much greater demand for its delivery devices.

Nu-Med Plus CEO Jeff Robins said: “With large gas supply companies entering the medical nitric oxide market we are ideally positioned to partner with them to sell our delivery systems with their gases. The result is a win-win situation for patients and business. As activity in the medical nitric oxide market increases, treatment costs will go down.”

As a medically essential gas, nitric oxide is always in demand. Currently, patients suffering from neonatal hypoxia-ischemia, chronic obstructive pulmonary disease (COPD) and other pulmonary problems rely on inhaled nitric oxide (INO) therapy.

New potential applications for the gas in treating a variety of other diseases and complications are currently being investigated.

Currently available INO delivery systems can be a concern for hospitals due to issues with usage, tracking, storage and the necessity of returning empty compressed gas tanks. Nu-Med Plus claims existing systems are large and awkward to use, which can impair patient mobility within the hospital, and makes taking INO outside the hospital environment nearly impossible. The company believes its products offer solutions to these issues.

According to reports in May, the invalidation of a patent covering Mallinckrodt Pharmaceuticals’ nitric oxide vasodilator Inomax has also opened the door for US-based industrial gas firm Praxair to bring a generic version of the device to market.